NXL Market Analysis
News & Sentiment
50 articles · sorted by dateVia 3rd party. Not a recommendation or advice by The Balanced Investor Club. See disclaimer.
Fundamentals
Updated daily after market closeValuation
- Forward P/E
- —
- PEG ratio
- —
- P/B
- 2.60
- P/S (TTM)
- 19.66
- EV/EBITDA
- 0.02
Profitability & growth
- ROE (TTM)
- -240.2%
- Operating margin
- -18480.0%
- Revenue growth YoY
- -82.8%
- Dividend yield
- —
- Beta
- 3.98
Ratios are point-in-time. Historical metrics — no guarantees about what comes next.
About Nexalin Technology Inc.
Company profileNexalin Technology Inc. is a pioneering medical technology firm dedicated to transforming the treatment of neurological and psychiatric disorders through its proprietary transcranial electrical stimulation devices. By offering non-invasive solutions for prevalent mental health issues such as anxiety, depression, and substance addiction, the company underscores its commitment to improving patient outcomes and advancing accessible mental health care. With a robust research background and a strategic focus on tapping into the rising demand for innovative healthcare solutions, Nexalin is…
Classification
- Sector
- Healthcare
- Industry
- Medical Devices
- Exchange
- NASDAQ
- Country
- USA
- Currency
- USD
Company profile
- HQ
- 1776 YORKTOWN, HOUSTON, TX
- Fiscal year end
- December
- Latest quarter
- Jun 30, 2026
We're educators, not advisors. We don't make buy or sell recommendations under any circumstance. All content is for educational purposes. Past performance doesn't guarantee future results. Your decisions are your own. Disclaimer